Supplementary video 2 from Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy

Supplementary video 2 from Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy

<p>Video S2</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Alvaro Teijeira (14962650) (author)
Andere auteurs:	Saray Garasa (14962653) (author), Carlos Luri-Rey (14962656) (author), Carlos de Andrea (14962659) (author), Maria Gato (14962662) (author), Carmen Molina (14962665) (author), Tsuneyasu Kaisho (14962668) (author), Assunta Cirella (14962671) (author), Arantza Azpilikueta (14962674) (author), Steffanie K. Wculek (14962677) (author), Josune Egea (14962680) (author), Irene Olivera (14962683) (author), Inmaculada Rodriguez (14962686) (author), Ana Rouzaut (14962689) (author), Vladislav Verkhusha (14962692) (author), Karmele Valencia (14962695) (author), David Sancho (14962698) (author), Pedro Berraondo (14931434) (author), Ignacio Melero (14962701) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Immuno-oncology Immunology Dendritic cells Immune responses to cancer Immunotherapy Agonist antibodies Checkpoint blockade
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Supplementary video 1 from Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
door: Alvaro Teijeira (14962650)
Gepubliceerd in: (2025)

Supplementary video 3 from Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
door: Alvaro Teijeira (14962650)
Gepubliceerd in: (2025)

Global transcriptional reprogramming by cytomegalovirus infection suppresses MHC class II antigen presentation while enhancing migration machinery in murine dendritic cells
door: Rhys H Parry (22367851)
Gepubliceerd in: (2025)

TMS pulse propagates beginning in the axon terminal, subsequently activating soma and dendrites.
door: Nicholas Hananeia (22683665)
Gepubliceerd in: (2025)

Distal LTP induced by simulated rMS is sustained by sodium dendritic spikes but less affected by inhibition than local electrical stimulation.
door: Nicholas Hananeia (22683665)
Gepubliceerd in: (2025)

Pharmacology in silico: rMS-induced LTP depends on dendritic sodium and calcium through voltage-gated calcium channels, as well as synaptic NMDA channels.
door: Nicholas Hananeia (22683665)
Gepubliceerd in: (2025)

Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
door: Alessio Cortellini (11023993)
Gepubliceerd in: (2025)

Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
door: Alessio Cortellini (11023993)
Gepubliceerd in: (2025)

Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
door: Alessio Cortellini (11023993)
Gepubliceerd in: (2025)

Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
door: Alessio Cortellini (11023993)
Gepubliceerd in: (2025)

Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
door: Alessio Cortellini (11023993)
Gepubliceerd in: (2025)

Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
door: Alessio Cortellini (11023993)
Gepubliceerd in: (2025)

Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
door: Alessio Cortellini (11023993)
Gepubliceerd in: (2025)

Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
door: Alessio Cortellini (11023993)
Gepubliceerd in: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
door: Santiago Duro-Sánchez (14959182)
Gepubliceerd in: (2025)

Data Sheet 1_Development of a nucleocapsid protein-based competitive ELISA for the detection of porcine deltacoronavirus antibodies.docx
door: Shuizhong Han (14027490)
Gepubliceerd in: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
door: Sheheryar Kabraji (15050565)
Gepubliceerd in: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
door: Xiaodong Shu (16721586)
Gepubliceerd in: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
door: Xiaodong Shu (16721586)
Gepubliceerd in: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
door: Xiaodong Shu (16721586)
Gepubliceerd in: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
door: Xiaodong Shu (16721586)
Gepubliceerd in: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
door: Xiaodong Shu (16721586)
Gepubliceerd in: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
door: Xiaodong Shu (16721586)
Gepubliceerd in: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
door: Xiaodong Shu (16721586)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_jpuep8vlsq42a8pq6em5rf9gp8